Citi raises target price of AKESO (09926) to HK$112.6, maintains "outperform" rating.
On April 23rd, ConBio announced that its phase III head-to-head trial HARMONi6 evaluating the efficacy of PD-1/VEGF AK112 combination therapy with BeiGene's PD-1 tislelizumab combination therapy in 1L sNSCLC achieved strong positive results.
CICC CCB International released a research report stating that it has raised the target price of AKESO (09926) by 18% from 95.3 Hong Kong dollars to 112.6 Hong Kong dollars, maintaining a "outperform" rating. The report pointed out that on April 23, AKESO announced that its Phase III head-to-head trial HARMONi6 evaluating the efficacy of PD-1/VEGF AK112 combination chemotherapy compared to BEIGENEPD-1 Tremelimumab monotherapy combined chemotherapy in 1L sNSCLC has achieved strong positive results and met the primary endpoint of progression-free survival (PFS) earlier than expected by the bank, which is expected to have a positive impact on sales growth. Therefore, the bank has adjusted its forecasts for this event.
RECOMMEND
Federal Reserve's Harker: Fed may cut interest rates in June if economic data is clear
24/04/2025
The big stick of tariffs cannot suppress the wave of AI-driven technology replacement. Is Apple Inc. entering a climax of stock price rebound with the "fruit chain"?
24/04/2025
Pan Gongsheng: There are no winners in a trade war or tariff war. China will continue to adhere to its policy of opening up to the outside world.
24/04/2025
